ANI Pharmaceuticals, Inc. (ANIP)
USD 67.99
(4.41%)
USD 67.99
(4.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 195.98 Million USD | -3.62% |
| 2022 | 203.33 Million USD | 41.5% |
| 2021 | 143.69 Million USD | 4.97% |
| 2020 | 136.88 Million USD | 7.81% |
| 2019 | 126.96 Million USD | 36.24% |
| 2018 | 93.19 Million USD | 35.89% |
| 2017 | 68.57 Million USD | 29.2% |
| 2016 | 53.07 Million USD | 71.61% |
| 2015 | 30.93 Million USD | 26.29% |
| 2014 | 24.49 Million USD | 27.49% |
| 2013 | 19.21 Million USD | -24.58% |
| 2012 | 25.47 Million USD | -50.36% |
| 2011 | 51.31 Million USD | 12.0% |
| 2010 | 45.81 Million USD | 15.45% |
| 2009 | 39.68 Million USD | 82.08% |
| 2008 | 21.79 Million USD | 137.61% |
| 2007 | 9.17 Million USD | -16.61% |
| 2006 | 10.99 Million USD | 15.04% |
| 2005 | 9.56 Million USD | -22.55% |
| 2004 | 12.34 Million USD | 101.99% |
| 2003 | 6.11 Million USD | -8.02% |
| 2002 | 6.64 Million USD | 46.58% |
| 2001 | 4.53 Million USD | 22.88% |
| 2000 | 3.68 Million USD | 129.87% |
| 1999 | 1.6 Million USD | -42.32% |
| 1998 | 2.78 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 58.53 Million USD | 7.74% |
| 2024 Q2 | 60.11 Million USD | 2.71% |
| 2023 FY | 195.98 Million USD | -3.62% |
| 2023 Q1 | 57.09 Million USD | 7.94% |
| 2023 Q2 | 60.82 Million USD | 6.54% |
| 2023 Q3 | 68.33 Million USD | 12.35% |
| 2023 Q4 | 54.32 Million USD | -20.5% |
| 2022 Q4 | 52.89 Million USD | 1.91% |
| 2022 FY | 203.33 Million USD | 41.5% |
| 2022 Q3 | 51.9 Million USD | 4.05% |
| 2022 Q1 | 48.64 Million USD | 2.35% |
| 2022 Q2 | 49.88 Million USD | 2.55% |
| 2021 Q1 | 31.49 Million USD | -1.39% |
| 2021 Q2 | 33.46 Million USD | 6.27% |
| 2021 FY | 143.69 Million USD | 4.97% |
| 2021 Q3 | 31.21 Million USD | -6.74% |
| 2021 Q4 | 47.53 Million USD | 52.29% |
| 2020 Q2 | 39.08 Million USD | 9.13% |
| 2020 Q1 | 35.81 Million USD | 3.01% |
| 2020 Q3 | 30.05 Million USD | -23.09% |
| 2020 FY | 136.88 Million USD | 7.81% |
| 2020 Q4 | 31.93 Million USD | 6.24% |
| 2019 FY | 126.96 Million USD | 36.24% |
| 2019 Q4 | 34.76 Million USD | 19.86% |
| 2019 Q2 | 29.43 Million USD | -12.82% |
| 2019 Q3 | 29 Million USD | -1.45% |
| 2019 Q1 | 33.76 Million USD | 32.16% |
| 2018 Q1 | 19.25 Million USD | 3.75% |
| 2018 Q3 | 24.98 Million USD | 6.71% |
| 2018 Q2 | 23.41 Million USD | 21.6% |
| 2018 FY | 93.19 Million USD | 35.89% |
| 2018 Q4 | 25.54 Million USD | 2.24% |
| 2017 Q4 | 18.55 Million USD | 4.52% |
| 2017 FY | 68.57 Million USD | 29.2% |
| 2017 Q3 | 17.75 Million USD | 6.65% |
| 2017 Q2 | 16.64 Million USD | 6.6% |
| 2017 Q1 | 15.61 Million USD | 17.28% |
| 2016 Q2 | 14.34 Million USD | 24.99% |
| 2016 Q1 | 11.47 Million USD | 39.53% |
| 2016 FY | 53.07 Million USD | 71.61% |
| 2016 Q4 | 13.31 Million USD | -4.44% |
| 2016 Q3 | 13.93 Million USD | -2.88% |
| 2015 Q1 | 6.48 Million USD | -1.68% |
| 2015 Q2 | 7.96 Million USD | 22.84% |
| 2015 FY | 30.93 Million USD | 26.29% |
| 2015 Q3 | 8.26 Million USD | 3.77% |
| 2015 Q4 | 8.22 Million USD | -0.41% |
| 2014 Q3 | 6.12 Million USD | -12.35% |
| 2014 Q2 | 6.99 Million USD | 46.17% |
| 2014 Q4 | 6.59 Million USD | 7.59% |
| 2014 Q1 | 4.78 Million USD | 8.98% |
| 2014 FY | 24.49 Million USD | 27.49% |
| 2013 Q1 | 3.08 Million USD | -44.89% |
| 2013 FY | 19.21 Million USD | -24.58% |
| 2013 Q4 | 4.38 Million USD | -0.2% |
| 2013 Q3 | 4.39 Million USD | -43.83% |
| 2013 Q2 | 7.82 Million USD | 153.53% |
| 2012 Q4 | 5.6 Million USD | 2.89% |
| 2012 Q2 | 7.37 Million USD | 4.72% |
| 2012 Q1 | 7.04 Million USD | -16.67% |
| 2012 FY | 25.47 Million USD | -50.36% |
| 2012 Q3 | 5.44 Million USD | -26.2% |
| 2011 Q3 | 13.21 Million USD | 0.49% |
| 2011 Q1 | 16.49 Million USD | 23.95% |
| 2011 FY | 51.31 Million USD | 12.0% |
| 2011 Q4 | 8.45 Million USD | -36.0% |
| 2011 Q2 | 13.14 Million USD | -20.33% |
| 2010 Q2 | 10.24 Million USD | -8.89% |
| 2010 FY | 45.81 Million USD | 15.45% |
| 2010 Q1 | 11.23 Million USD | -54.01% |
| 2010 Q4 | 13.31 Million USD | 17.89% |
| 2010 Q3 | 11.29 Million USD | 10.26% |
| 2009 Q1 | 4.13 Million USD | -24.47% |
| 2009 FY | 39.68 Million USD | 82.08% |
| 2009 Q3 | 6.38 Million USD | 34.74% |
| 2009 Q2 | 4.73 Million USD | 14.65% |
| 2009 Q4 | 24.43 Million USD | 282.95% |
| 2008 Q3 | 6.77 Million USD | 22.27% |
| 2008 Q2 | 5.53 Million USD | 38.03% |
| 2008 Q1 | 4.01 Million USD | 71.35% |
| 2008 FY | 21.79 Million USD | 137.61% |
| 2008 Q4 | 5.46 Million USD | -19.26% |
| 2007 Q2 | 2.7 Million USD | 39.25% |
| 2007 Q3 | 2.19 Million USD | -18.86% |
| 2007 Q1 | 1.93 Million USD | -52.83% |
| 2007 Q4 | 2.34 Million USD | 6.9% |
| 2007 FY | 9.17 Million USD | -16.61% |
| 2006 Q1 | 3.4 Million USD | 80.42% |
| 2006 FY | 10.99 Million USD | 15.04% |
| 2006 Q3 | 1 Million USD | -59.2% |
| 2006 Q4 | 4.11 Million USD | 307.92% |
| 2006 Q2 | 2.47 Million USD | -27.54% |
| 2005 Q2 | 2.72 Million USD | -5.8% |
| 2005 Q4 | 1.88 Million USD | -7.58% |
| 2005 Q1 | 2.89 Million USD | -32.07% |
| 2005 Q3 | 2.04 Million USD | -25.08% |
| 2005 FY | 9.56 Million USD | -22.55% |
| 2004 Q2 | 2.63 Million USD | 6.25% |
| 2004 Q3 | 2.96 Million USD | 12.53% |
| 2004 Q4 | 4.26 Million USD | 43.85% |
| 2004 FY | 12.34 Million USD | 101.99% |
| 2004 Q1 | 2.47 Million USD | 46.69% |
| 2003 Q1 | 1.32 Million USD | -41.0% |
| 2003 FY | 6.11 Million USD | -8.02% |
| 2003 Q4 | 1.69 Million USD | 15.45% |
| 2003 Q3 | 1.46 Million USD | -10.03% |
| 2003 Q2 | 1.62 Million USD | 22.47% |
| 2002 FY | 6.64 Million USD | 46.58% |
| 2002 Q4 | 2.25 Million USD | 27.74% |
| 2002 Q3 | 1.76 Million USD | 17.41% |
| 2002 Q2 | 1.5 Million USD | 36.19% |
| 2002 Q1 | 1.1 Million USD | -23.43% |
| 2001 Q1 | 722 Thousand USD | -27.54% |
| 2001 Q4 | 1.44 Million USD | -1.42% |
| 2001 FY | 4.53 Million USD | 22.88% |
| 2001 Q3 | 1.46 Million USD | 60.6% |
| 2001 Q2 | 909.75 Thousand USD | 26.0% |
| 2000 Q4 | 996.4 Thousand USD | 46.33% |
| 2000 Q1 | 516.2 Thousand USD | 0.0% |
| 2000 FY | 3.68 Million USD | 129.87% |
| 2000 Q3 | 680.92 Thousand USD | -54.47% |
| 2000 Q2 | 1.49 Million USD | 189.75% |
| 1999 FY | 1.6 Million USD | -42.32% |
| 1999 Q2 | 326.16 Thousand USD | 0.0% |
| 1998 FY | 2.78 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -2274.725% |
| Alpha Teknova, Inc. | 45.85 Million USD | -327.36% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -336.935% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -23.099% |
| Cosmos Health Inc. | 26.18 Million USD | -648.576% |
| Journey Medical Corporation | 54.59 Million USD | -258.983% |
| Embecta Corp. | 528.4 Million USD | 62.91% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 27.92% |
| Dynavax Technologies Corporation | 219.14 Million USD | 10.569% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 66.783% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 39.952% |
| PainReform Ltd. | 9.58 Million USD | -1944.898% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1393.264% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1393.264% |
| SCYNEXIS, Inc. | 51.84 Million USD | -277.995% |
| Safety Shot Inc | 12.1 Million USD | -1518.398% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -6285.5% |
| Procaps Group, S.A. | 199.47 Million USD | 1.752% |
| Theratechnologies Inc. | 72.75 Million USD | -169.37% |
| Harrow Health, Inc. | 89.97 Million USD | -117.824% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1974.772% |
| Biofrontera Inc. | 39.95 Million USD | -390.46% |
| DURECT Corporation | 43.71 Million USD | -348.32% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 62.953% |
| Cronos Group Inc. | 96.7 Million USD | -102.652% |
| OptiNose, Inc. | 85.1 Million USD | -130.292% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 15.57% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -400.557% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2149.817% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 37.612% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1914.041% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -355.345% |
| Radius Health, Inc. | 265.92 Million USD | 26.303% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1315.867% |
| ProPhase Labs, Inc. | 37.85 Million USD | -417.761% |
| Phibro Animal Health Corporation | 260.29 Million USD | 24.708% |
| Procaps Group S.A. | 187.24 Million USD | -4.667% |
| Alvotech | 285.43 Million USD | 31.34% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1894.738% |
| Viatris Inc. | 5.96 Billion USD | 96.715% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1174.769% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -227.512% |
| SIGA Technologies, Inc. | 22.04 Million USD | -789.093% |
| Tilray Brands, Inc. | 251.35 Million USD | 22.03% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -299.655% |
| Shineco, Inc. | 17.94 Million USD | -991.947% |
| PetIQ, Inc. | 192.72 Million USD | -1.69% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -4810.454% |
| Incannex Healthcare Limited | 30.05 Million USD | -552.125% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 87.724% |
| Alimera Sciences, Inc. | 62.64 Million USD | -212.867% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -25602.958% |
| Assertio Holdings, Inc. | 368.58 Million USD | 46.828% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -3229.889% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1000.501% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -825.802% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -831.385% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -18.802% |
| Hempacco Co., Inc. | 7.59 Million USD | -2479.929% |
| Talphera, Inc. | 11.99 Million USD | -1534.009% |
| Alvotech | 285.43 Million USD | 31.34% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -39.278% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 43.177% |
| Currenc Group, Inc. | 24 Million USD | -716.525% |
| Kamada Ltd. | 45.42 Million USD | -331.434% |
| Indivior PLC | 911 Million USD | 78.487% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1479.28% |
| Flora Growth Corp. | 10.57 Million USD | -1752.566% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -831.385% |
| Evolus, Inc. | 189.75 Million USD | -3.28% |
| HUTCHMED (China) Limited | 436.23 Million USD | 55.074% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -27.151% |
| Akanda Corp. | 3.48 Million USD | -5526.024% |